Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 291 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antidepressant + placebo Clear all
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
saredutant (SR48968), escitalopram, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neurotrophic Factors and Depression

NCT00812994
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436162
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial of Pramipexole in Bipolar Depression

NCT00025792
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Pramipexole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT01173601
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Irvine, California • La Habra, California • Redlands, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

Effects Of Antidepressants On Sexual Functioning In Adults

NCT00051272
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 2, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

NCT04423757
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Results available

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

NCT00536172
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

NCT02484456
View directory record Official record
Conditions
Major Depression
Interventions
AV 101 (4-Chlorokynurenine), Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Aripiprazole Augmentation of Antidepressants in PTSD

NCT00489866
View directory record Official record
Conditions
PTSD
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01435759
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
60
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 2, 2026, 5:06 AM EDT
Terminated Phase 3 Interventional Results available

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

NCT00868374
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Keming Gao
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Rapid Antidepressant Effects of Ketamine in Major Depression

NCT00088699
View directory record Official record
Conditions
Depression, Mood Disorders, Major Depresssion
Interventions
Ketamine, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 2, 2026, 5:06 AM EDT
Terminated Phase 1 Interventional

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

NCT04951609
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Anaheim, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

NCT03018340
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress and Inflammation in Late-Life Depression

NCT02389465
View directory record Official record
Conditions
Depression, Inflammation
Interventions
Escitalopram + Celecoxib, Escitalopram + Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 2, 2026, 5:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Neuroimaging Study of Open-label Placebo in Depressed Adolescents

NCT04201106
View directory record Official record
Conditions
Depression
Interventions
Open Label Placebo with Rationale, Open Label Placebo without Rationale
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 5:06 AM EDT
Withdrawn Phase 2 Interventional

N2O for Acute Suicidality and Depression in the ED

NCT05710887
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

NCT01364649
View directory record Official record
Conditions
Treatment Outcome
Interventions
Vortioxetine, Escitalopram, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 2, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

NCT02932943
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 2, 2026, 5:06 AM EDT